Predictors of amnesic mild cognitive impairment to dementia progression: A two-year prospective study;Czynniki prognostyczne progresji amnestycznych łagodnych zaburzeń poznawczych w dwuletniej obserwacji podłużnej

Postepy Psychiatrii i Neurologii

Volumn 16, Issue 2, 2007, Pages 133-138

  Sobów, Tomasz ^a   Kłoszewska, Iwona ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Dementia; Mild cognitive impairment; Progression; Prospective study; Risk factors

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42];

ACADEMIC ACHIEVEMENT; AGE; AGED; AMNESIA; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL OBSERVATION; COGNITIVE DEFECT; COHORT ANALYSIS; COLORIMETRY; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DEMOGRAPHY; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENDER; HUMAN; MEDICAL CARE; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; PATIENT REFERRAL; PATIENT SELECTION; PREDICTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PSYCHOMETRY; RISK ASSESSMENT;

EID: 77953410040     PISSN: 12302813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56: 303-8.
2. Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili F, Scheltens P, Vellas B, Touchon J. MCI Working Group of the European Consortium on Alzheimer's Disease (EADC). Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry 2006; 77: 714-8.
3. Bidzan L, Bidzan M. Rokowanie w łagodnych zaburzeniach poznawczych. Psychiatr Pol 2004; 38: 251-62.
4. Gabryelewicz T. Łagodne zaburzenia poznawcze. Akt Neurol 2004; 4: 167-71.
5. Amieva H, Letenneur L, Dartigues JF, Rouch-Leroyer I, Sourgen C, D'Alchee-Biree F, Dib M, Barberger-Gateau P, Orgogozo JM, Fabrigoule C. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geriatr Cogn Disord 2004; 18: 87-93.
6. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58: 397-405.
7. Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, Barberger-Gateau P, Dartigues JF. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort, Neurology 2002; 59: 1594-9.
8. Tierney MC, Szalai JP, Snow WG, Fisher RH, Nores A, Nadon G, Dunn E, St George-Hyslop PH. Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study. Neurology 1996; 46: 661-5.
9. Bozoki A, Giordani B, Heidebrink JL, Berent S, Foster NL. Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol 2001; 58: 411-6.
10. Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B. Neuropsychological prediction of decline to dementia in non-demented elderly. J Geriatr Psychiatry Neurol 1999; 12: 168-79.
11. Arnaiz E, Almkvist O. Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease. Acta Neurol Scand Suppl 2003; 179: 34-41.
12. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 2004; 16: 129-40.
13. Almkvist O, Basun H, Backman L, Herlitz A, Lannfelt L, Small B, Viitanen M, Wahlund LO, Winblad B. Mild cognitive impairment - an early stage of Alzheimer's disease? J Neural Transm Suppl 1998; 54: 21-9.
14. Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl 2003; 179: 52-76.
15. Flirski M, Sobów T. Biochemical markers and risk factors of Alzheimer's disease. Curr Alzheimer Res 2005; 2: 47-64.
16. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002; 59: 1729-34.
17. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl 2003; 179: 47-51.
18. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Moller HJ, Blennow K, Buerger K. Value of CSF beta-amyloid 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004; 9: 705-10.
19. Borroni B, Colciaghi F, Caltagirone C, Rozzini L, Broglio L, Cattabeni F, Di Luca M, Padovani A. Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: a 2-year follow-up study. Arch Neurol 2003; 60: 1740-4.
20. Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R, Inglese ML, Volpe S, Ratto S, Dagna-Bricarelli F, Baldo C, Argusti A, Odetti P, Piccini A, Tabaton M. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 2004; 63: 828-31.
21. Sobów T, Flirski M, Kłoszewska I, Liberski PP. Plasma levels of Aβ peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp (Wars) 2005; 65: 117-24.
22. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, Quadri P, Forloni G, Mariani C. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2006; 27: 904-5.
23. Mayeux R, Tang MX, Jacobs DM, i wsp. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 1999; 46: 412-6.
24. Graff-Radford N, Ertekin-Taner N, Jadeja N, Younkin L, Younkin S. Evidence that plasma amyloid beta protein may be useful as a premorbid biomarker for Alzheimer's disease. Neurobiol Aging 2002; 23: S384.
25. Luis CA, Barker WW, Loewenstein DA, Crum TA, Rogaeva E, Kawarai T, St George-Hyslop P, Duara R. Conversion to dementia among two groups with cognitive impairment. A preliminary report. Dement Geriatr Cogn Disord 2004; 18: 307-13.
26. Keller HH, Ostbye T. Body Mass Index (BMI), BMI change and mortality in community-dwelling seniors without dementia. J Nutr Health Aging 2005; 9: 316-20.
27. Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS, Markesbery WR. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology 2006; 66: 828-32.
28. Bhargava D, Weiner MF, Hynan LS, Diaz-Arrastia R, Lipton AM. Vascular disease and risk factors, rate of progression and survival in Alzheimer's disease. J Geriatr Psychiatry Neurol 2006; 19: 78-82.
29. Solfrizzi V, Panza F, Colacicco AM, D'Introno A, Capurso C, Torres F, Grigoletto F, Maggi S, Del Parigi A, Reiman EM, Caselli RJ, Scafato E, Farchi G, Capurso A. Italian Longitudinal Study on Aging Working Group. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004; 63: 1882-91.
30. Nourhashemi F, Deschamps V, Larrieu S, Letenneur L, Dartigues JF, Barberger-Gateau P. PAQUID study. Personnes Agees Quid. Body mass index and incidence of dementia: the PAQUID study. Neurology 2003; 60: 117-9.
31. Irizarry MC, Muzikansky A, Lee H, Raju S, Bottiglieri T, Hyman BT, Albert MA, Blacker D. Longitudinal changes in plasma Aβ42 positively correlate with progression of milf cognitive impairment. Poster przedstawiony podczas 10th International Conference on Alzheimer's Disease and Related Disorders, Madryt, Hiszpania, 15-20.07.2006 r. Alzheimer's Dementia 2006; 3 (supl): 402.
32. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003; 61: 1185-90.
33. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 2003; 60: 958-64.
34. Sundelof JE, Giedraitis V, Irizarry MC, Sundstrom J, Ingelsson E, Ronnemaa E, Gunnarsson MD, Hymat BT, Basun H, Ingelsson M, Kilander L, Lannfelt L. Differential regulation of plasma Aβ40 and Aβ42 levels with aging in the Uppsala longitudinal study of adult men (ULSAM). Poster przedstawiony podczas 10th International Conference on Alzheimer's Disease and Related Disorders, Madryt, Hiszpania, 15-20.07.2006 r. Alzheimer's Dementia 2006; 3 (supl): 398.
35. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 2001; 304: 102-6.
36. Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P. 30 monts prospective study on plasma amyloid beta protein 42, medial temporal lobe atrophy and change of cognition in the VITA cohort. Poster przedstawiony podczas 10th International Conference on Alzheimer's Disease and Related Disorders, Madryt, Hiszpania, 15-20.07.2006 r. Alzheimer's Dementia 2006; 3 (supl): 399.
37. Graff-Radford NR, Weigand SD, Shuing MM, Knopman DS, Boeve BF, Lucas JA, Crook JE, Younkin LH, Petersen RC, Jack CR, Younkin SG. Annualized decrease in plasma Aβ42 correlates with annualized decrease in hippocampal volume. Poster przedstawiony podczas 10th International Conference on Alzheimer's Disease and Related Disorders, Madryt, Hiszpania, 15-20. 07.2006 r. Alzheimer's Dementia 2006; 3 (supl): 403.